Keyword: Agios Pharmaceuticals
Swedish p53 cancer biotech Aprea Therapeutics has nabbed former Agios senior medical director Eyal Attar as its senior vice president and chief medical officer.
Tibsovo won't be a blockbuster with peak sales hovering around the $300 million mark, but it’s still on the hook to treat around 700 to 1,100 AML patients with the IDH1 mutation in the U.S.
Sean Harper to help run $320M VC fund; Agios crowns Jackie Fouse as CEO; and hospital-backed Civica Rx nabs Amgen vet as CEO.
After a major melt down at Axovant with failures and a fleeing CEO, the "vant" family is losing another star biotech player in Jackie Fouse.
After a tough few months, sources are telling the Financial Times that Celgene is looking to buy out some biotech names with ties to the company.
Hal Barron replaces Patrick Vallance as GSK CSO, Biogen lured Merck exec to head global marketing and Celgene vet Pehl lands at Immunomedics.
Agios and Shire veteran Ann Barbier, M.D., Ph.D., has become the new chief medical officer at RNA biotech Translate Bio.
Shares in Agios have fallen after a preview of ASH data that will be used to support an FDA filing for refractory acute myeloid leukemia candidate ivosidenib.
The deal will see Thermo Fisher validate and seek approval for a test to identify RET fusions in non-small cell lung cancer patients.
Celgene has reached its first licensing agreement in the Asia-Pacific region with Antengene, and CRO Tigermed will help with clinical studies.